Biotech & Life Sciences

Geneva researchers find metastasis runs on a gradient, not a switch — and built an AI to read it A University of Geneva team cloned individual cancer cells to discover that tumor spread depends on collective cell behavior, then turned that insight into a prediction tool that outperforms existing...

Massachusetts hospitals are diagnosing more patients with sepsis than ever.

Children born without a functioning esophagus may someday get a new one grown from their own cells and a pig-derived scaffold.

The FDA fastest approval pathway is opening itself up to public scrutiny — and the early results suggest it actually works. Commissioner Marty Makary National Priority Voucher pilot program, launched in June 2025, has awarded 18 vouchers and produced four approved drugs in less than a year, the ...

A biotech company that bridges American capital and Chinese science has raised $787 million and is weighing a Hong Kong listing — exactly the kind of cross-border deal that is becoming harder to do. Earendil Labs announced the financing round Thursday, with participation from Sanofi, the Biotech...

Medicinal cannabis has been sold to millions of people as a treatment for anxiety, depression, and PTSD.

The shingles vaccine may do more than prevent shingles.

MilliporeSigma Is Betting $120 Million That the FDA Means It About Ending Animal Testing The morning after the FDA issued its most concrete blueprint yet for replacing animal studies with human-based testing methods, one of the world's largest life sciences suppliers is quietly operating the bet...

Clarissa Desjardins's new company has dosed its first subjects in a Phase 1 trial of an oral genetic obesity drug — a pharmacological corrector that takes a fundamentally different approach from GLP-1 agonists.

AstraZeneca deepens UK-China ties with cell therapy R&D hub, manufacturing plans The British drugmaker said Thursday it will build a cell therapy manufacturing and supply base and an innovation centre in Shanghai, aiming to become the first global pharmaceutical company with end-to-end cell ther...

A team from Mass General Brigham and Dana-Farber Cancer Institute has published results in Cell showing that a single injection of an oncolytic herpes simplex virus can recruit immune cells into glioblastoma tumors and extend survival in a Phase 1 trial — offering a rare bright spot in a cancer t...